Sign In
Buy BHC
$4.95
-0.0600 (-1.20%)
At Close: Jun 03, 2026
InflammX Therapeutics Announces Option Agreement with Bausch + Lomb
08:30am, Friday, 10'th Jan 2025
TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- InflammX Therapeutics Inc., a clinical-stage biotechnology company focused on developing innovative therapies for retinal diseases with significant unmet
CAMBRIDGE, Mass.--(BUSINESS WIRE)--City Therapeutics, Inc., a privately held biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, today announced that it has entered
Here's Why Bausch Health (BHC) is a Strong Momentum Stock
10:51am, Thursday, 09'th Jan 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Bausch + Lomb and Glaucoma Research Foundation Launch Second Annual “Faces of Glaucoma” Campaign and Fundraising Challenge
07:00am, Tuesday, 07'th Jan 2025
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, and Glaucoma Research Foundati
Bausch + Lomb to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
07:00am, Thursday, 02'nd Jan 2025
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman
Contact lens maker Bausch + Lomb says it is exploring sale
02:18pm, Thursday, 12'th Dec 2024
Bausch + Lomb is exploring a potential sale among other options, it said on Thursday, in a move that would help Canadian parent Bausch Health exit the eye-care company.
Bausch + Lomb Responds to Rumors of a Potential Sale
07:00am, Thursday, 12'th Dec 2024
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, issued the following statement
Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb
07:00am, Thursday, 12'th Dec 2024
LAVAL, QC / ACCESSWIRE / December 12, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a
Macy's, Dave & Buster's, Bausch + Lomb And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
08:46am, Wednesday, 11'th Dec 2024
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 50 points on Wednesday.
Bausch + Lomb And Bausch Health: Some Incremental Progress As We Wait For Sale News
07:30pm, Friday, 06'th Dec 2024
Bausch Health Companies Inc.'s debt burden remains a critical issue, with over $21 billion in long-term debt, making a sale of Bausch + Lomb Corporation a potential solution. Bausch + Lomb's Q3 perfor
LAVAL, QC / ACCESSWIRE / December 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), alongside the U.S. Pain Foundation
Bausch Health Companies: Improving Core Business Cures Its Bankruptcy Rumors
10:21pm, Monday, 02'nd Dec 2024
Bausch Health Companies is undervalued, with a positive outlook for 2024 and solvency reassurance for 2025. The complete spin-off of Bausch + Lomb (B+L) will benefit BHC and is expected to improve its
Why Is Bausch (BHC) Down 11.7% Since Last Earnings Report?
12:37pm, Friday, 29'th Nov 2024
Bausch (BHC) reported earnings 30 days ago. What's next for the stock?
Bausch (BHC) Upgraded to Buy: Here's What You Should Know
01:01pm, Monday, 25'th Nov 2024
Bausch (BHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
US Supreme Court declines to hear patent dispute over Bausch blockbuster diarrhea drug
09:49am, Monday, 18'th Nov 2024
The U.S. Supreme Court turned away on Monday a bid by Alvogen's subsidiary Norwich Pharmaceuticals to sell a generic version of Canada-based Bausch Health's blockbuster diarrhea drug Xifaxan.
